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 47 
Abstract 48 
Guidelines may reduce practice variation and optimize patient care. We aimed to study 49 
differences in guideline use in the management of traumatic brain injury (TBI) patients and 50 
analyze reasons for guideline non-adherence.  51 
As part of a prospective, observational, multi-center European cohort study, participants from 52 
68 centers in 20 countries were asked to complete 72-item questionnaires regarding their 53 
management of severe TBI. Six questions with multiple sub-questions focused on guideline 54 
use and implementation.  55 
Questionnaires were completed by 65 centers. Of these, 49 (75%) reported use of the Brain 56 
Trauma Foundation Guidelines for the medical management of TBI or related institutional 57 
protocols, 11 (17%) used no guidelines and 5 used other guidelines (8%). Of 54 centers 58 
reporting use of any guidelines, 41 (75%) relied on written guidelines. Four centers of the 54 59 
(7%) reported no formal implementation efforts. Structural attention to the guidelines during 60 
daily clinical rounds was reported by 21 centers (38%). The most often reported reasons for 61 
non-adherence were ‘every patient is unique’ and the presence of extracranial injuries, both 62 
for centers that did and did not report the use of guidelines. 63 
There is substantial variability in the use and implementation of guidelines in neurotrauma 64 
centers in Europe. Further research is needed to strengthen the evidence underlying guidelines 65 
and to overcome implementation barriers. 66 
 67 
68 
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Introduction 69 
The objective of clinical practice guidelines is to reduce practice variations and improve 70 
patient outcomes by synthesizing the best available evidence in clear, concise and easy-to-use 71 
documents
1
. The Brain Trauma Foundation (BTF) Guidelines for the medical management of 72 
severe traumatic brain injury (TBI) are the most widely used for these patients with 4 editions 73 
published over the last 20 years
2
. Recent studies show suboptimal and variable adherence 74 
rates, which likely relate both to the poor quality of the evidence and the heterogeneity of the 75 
TBI patient population, among other reasons
3-6
.  76 
Within a prospective, observational study, the Collaborative European NeuroTrauma 77 
Effectiveness Research in TBI study (CENTER-TBI; www.center-tbi.eu), we aimed to 78 
explore variations in guideline use and implementation strategies for severe TBI in Europe, in 79 
particular adherence to the high quality recommendations (levels I and II). We then aimed to 80 
detect differences in practice between centers that use BTF guidelines and those that use other 81 
guidelines.  82 
 83 
Materials and Methods 84 
We approached the principal investigators (PIs) of 68 centers from 20 European countries, 85 
participating in the CENTER-TBI study between 2014 and 2015. Of these, 65 completed the 86 
questionnaires.  PIs were asked to complete a set of questionnaires about structure and 87 
processes of care. In the item generation phase we have gathered experts together within the 88 
CENTER-TBI team and proceeded with item generation and item reduction in a second 89 
phase. The questionnaires were then pre-tested with a group of participating centers and face 90 
validity was discussed with the participants and the experts involved in item generation. The 91 
pilot testing evaluated flow and time required to complete. 92 
We have measured reliability and concordance rates of the questionnaire.  To estimate 93 
reliability of the questionnaires, we included 17 (5%) duplicate questions, including all 94 
question formats. We equally included structure and process questions in the duplicate 95 
questions.  Concordance rates were estimated by calculating the percentage of overlap 96 
between duplicate questions, and presented as mean, median and range. Questionnaires were 97 
disseminated during presentations, workshops and email conversations. More information is 98 
available at length in one of our group’s previous publications3.  99 
A set of questionnaires designed to measure structure and process of TBI care was developed 100 
on the basis of available literature, expert opinion and based on best practice
7
. These 101 
questionnaires were comprehensively described in a previous publication
3
. Pilot testing was 102 
undertaken in 16 of the participating centers, and feedback was incorporated into the final 103 
questionnaire design. 104 
The questionnaire on ICU care contained 6 questions with multiple sub-questions exploring 105 
guideline use and implementation. In most questions the “general policy” at each center was 106 
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surveyed. This was defined as “routine policy”; the standard treatment or policy in a particular 107 
case. In others, we asked for quantitative estimations, whereby the frequency of using a 108 
treatment strategy could be indicated (never 0-10%, rarely 10-30%, sometimes 30-70%, 109 
frequently 70-90%, always 90-100%). The options ‘frequently’ and ‘always’ were interpreted 110 
as representing the general policy, in line with previous provider profiling studies
6
. The 111 
questions regarding the reasons for guideline-nonadherence also needed to be answered with 112 
quantitative estimations as stated above for each individual reason. The reasons given were: ” 113 
Lack of knowledge among clinicians”, “Every patient is unique and should be managed by 114 
clinical judgment”, “Inadequate time to consult guidelines for urgent decisions”, “Guidelines 115 
on TBI do not apply due to extracranial trauma or comorbidity”, “Inadequate resources to 116 
apply guidelines (ICU beds, personnel, equipment)” (See Supplemental Digital Content 1 for 117 
more details). 118 
We used chi-square and Fisher’s exact tests to compare therapies and monitoring at centers 119 
that used BTF or BTF-based guidelines with centers that used other or no guidelines for 120 
several recommendations from the two most recent versions of the BTF guidelines (2007 and 121 
2016, versions 3 and 4).  122 
Results 123 
Most participants reported use of either BTF Guidelines, or BTF-based institutional 124 
guidelines (n = 49; 75%), while 5 centers (8%) used non-BTF-based guidelines. 11 centers 125 
(17%) reported that they did not use any guidelines. No regional differences were observed 126 
between North – Western Europe (n = 30; 70%, use BTF Guidelines) and South – Eastern 127 
Europe (n=19; 83%, use BTF Guidelines).  128 
Of the 54 centers that reported to use guidelines, five had no allocation of responsibility to 129 
oversee guideline development and maintenance (9%). In other centers, guideline 130 
development and maintenance were the responsibility of a multi-disciplinary team (n = 31; 131 
56%). However, annual or more frequent audit of guideline adherence was reported in only 4 132 
centers (7%), while the remainder (n = 51; 93%) reported either no audits, or only one within 133 
the past five years.  134 
Four of the 54 centers using guidelines (7%) reported no formal implementation process. The 135 
majority (n = 41; 75%), had written protocols and algorithms, but less than half paid structural 136 
attention to the guidelines during rounds (n = 21; 38%) or organized hospital-led training (n = 137 
20; 36%). Twelve centers of the 55 (22%) had their protocol in a data management system. 138 
Five centers (9%) had e-learning modules or used trainings organized by an external 139 
organization (n = 3; 4%). 140 
The most often reported reasons for non-adherence were ‘every patient is unique’ (n = 19; 141 
39%) and the presence of extracranial injuries (n = 8; 16%), for both centers that use and for 142 
those that do not use guidelines (Figure 1). 143 
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When comparing centers that used BTF Guidelines (n = 49) with those that use other 144 
guidelines or none at all (n = 17), the only statistically significant difference in policy  was the 145 
use of levetiracetam for antiseizure prophylaxis (p = 0.04, Table 1).  146 
Overall, the estimated adherence to the medical management recommendations of the centers 147 
that use BTF guidelines was “always” (n = 10; 20%), “frequently” (n = 38; 78%) and 148 
sometimes (n = 1; 2%). 149 
Regarding ICP monitoring
8
 in patients with a Glasgow Coma Scale (GCS) < 9 and CT 150 
abnormalities, 44 centers that used BTF guidelines (90%) would monitor ICP as a general 151 
policy and 14 (93%) of those that used other guidelines or none at all. Of the 5 centers that 152 
used BTF guidelines and would not monitor ICP in such a patient, 4 (8%) reported to 153 
“frequently” adhere to medical management recommendations and 1 (2%) reported to 154 
“always” adhere to the recommendations.  155 
Corticosteroid use for the primary TBI was reported as “never” in 45 centers that used BTF 156 
guidelines (92%), “rarely” in 3 (6%) and “sometimes” in 1 (2%). Of the centers that use other 157 
guidelines or no guidelines, 12 “never” use corticosteroids for the primary TBI (75%), 2 158 
“rarely” (13%), 1 “sometimes” (6%) and 1 “frequently” (1%). 159 
Seven (15%) of the centers that used BTF guidelines and 5 (31%) of those who did not use 160 
BTF guidelines choose barbiturates as first tier therapy (p = 0.15). The seven centers that used 161 
BTF guidelines reported to “frequently” adhere to medical management recommendations.  162 
Five (10%) of the centers that used BTF guidelines and 5 (31%) of centers that do not use 163 
BTF Guidelines utilized hyperventilation as a first tier therapy (p=0.10). Of the 164 
aforementioned 5 centers that use BTF guidelines, 3 (6%) reported to “always” adhere to the 165 
medical management guidelines and 2 (4%) reported to “frequently” adhere to medical 166 
management guidelines.  167 
Seventeen (35%) of the centers that used BTF guidelines use phenytoin as the drug of choice 168 
for antiseizure prophylaxis and 3 (19%) centers who did not use the BTF guidelines. More 169 
than half of the centers that used BTF guidelines, however, used levetiracetam ( n = 28; 57%) 170 
as the drug of choice. Significantly fewer centers that did not use the BTF guidelines (n = 4; 171 
25%) used levetiracetam as the drug of choice.  172 
Discussion 173 
We found considerable variability in guideline adherence and implementation among 174 
neurotrauma centers in Europe. Less than one in three centers reported organized training, 175 
paid structural attention to guidelines during daily rounds, or had a protocol in their clinical 176 
data management system. However, though such implementation strategies would empirically 177 
seem to be useful, there are as yet no data suggesting benefit of any individual 178 
implementation or dissemination strategy in different circumstances
9
. 179 
With respect to the level II recommendations, several centers, both that use and that do not 180 
use BTF guidelines, used barbiturates and hyperventilation as a first – tier therapy, despite the 181 
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recommendation against this practice
10
. Despite the fact that proportionally more centers that 182 
do not use BTF guidelines use barbiturates and hyperventilation as first tier therapies, the 183 
difference did not reach statistical significance.  184 
The use of antiseizure prophylaxis was the only statistically significant association with 185 
guideline use in our data. The best available evidence supports using phenytoin as the drug of 186 
choice to prevent early post-traumatic seizures (PTS). In the 4
th
 edition of the BTF guidelines, 187 
published after our questionnaire, the authors conclude that there is insufficient evidence to 188 
recommend levetiracetam over phenytoin regarding efficacy in preventing early PTS and 189 
toxicity
2
. The fact that significantly more centers that use BTF guidelines use levetiracetam is 190 
likely due to its important role in contemporary epilepsy treatment and not the adherence to 191 
the recommendations of the BTF guidelines. Moreover, it is easier to use, as there is no need 192 
to monitor serum concentrations and is perceived as having a more favorable side effect 193 
profile
11-13
.     194 
The only level I recommendation, against the use of corticosteroids in primary TBI 195 
treatment
2
, is adhered to in 92 %.  196 
Both the use of levetiracetam and the approach to corticosteroids reflect more the applicability 197 
of the guidelines in a “real world” setting where pragmatic choices take precedence above 198 
guidelines recommendations based on the current evidence. Furthermore, the body of 199 
evidence against the use of corticosteroids
2,14
 for the primary treatment of TBI does not 200 
necessarily apply to entities such as late perifocal edema around a contusion. Moreover, the 201 
centers participating in this study are well-versed in the treatment of TBI and are involved in 202 
international clinical research. As such, the clinical decision making process is nuanced in 203 
these centers, and does not follow guidelines unequivocally. 204 
The reasons for non-adherence include patient heterogeneity and the presence of extracranial 205 
injury, which might indeed impose different priorities for care. Resource limitation was also 206 
mentioned as a problem in the centers that did not use guidelines. We anticipate that the 207 
relatively low adherence also stems from the general poor quality of evidence which 208 
underpins current TBI guidelines, although this argument was not specifically queried. 209 
Remarkably, we found no clear differences in management policies between centers that 210 
report to use or not to use BTF guidelines, save for the more frequent use of levetiracetam in 211 
centers adhering to BTF guidelines.  212 
We recognize that the questionnaire format of this study is a limitation in terms of properly 213 
auditing guideline use and adherence, together with the relatively low power. However, the 214 
centers involved in the CENTER-TBI project are frequently involved in TBI research, with 215 
broad exposure to the international TBI community, which might explain the lack of 216 
difference between centers that do and those that do not use guidelines in light of the evidence 217 
base
14
. Furthermore, the results also need to be interpreted in light of the fact that the 218 
questionnaires were filled in before the publication of the 4
th
 edition of the BTF Guidelines.  219 
Conclusion 220 
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There is substantial variability in reported guideline use, adherence, and implementation 221 
strategies and perceived barriers among neurotrauma centers in Europe. Further research first 222 
needs to strengthen the evidence base underpinning the guidelines, followed by addressing 223 
implementation barriers to develop optimal implementation strategies, in order to optimize 224 
clinical practice and potentially improve patient outcomes. 225 
 226 
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Figure 1- The reasons for nonadherence (and thus implementation barriers) reported by 266 
centers that do use guidelines (n=49) and those who do not use guidelines (n=10). 267 
Table 1 - The general policies of the centers studied in relation to the type of guideline they 268 
use. In most questions we aimed for a reflection of the “general policy” at each center. In 269 
others, however, we asked for quantitative estimations, whereby the frequency with which a 270 
treatment strategy was used could be indicated (never 0-10%, rarely 10-30%, sometimes 30-271 
70%, frequently 70-90%, always 90-100%). The options ‘frequently’ and ‘always’ were 272 
interpreted as representing the general policy 273 
 274 
Supplemental Digital Content Legend 275 
Supplemental Digital Content 1, Methods: The Provider Profiling ICU Questionnaire 276 
regarding treatment policy and guideline use 277 
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Treatment/Monitoring Total (% of 
total 
respondents) 
Centres using 
BTF guidelines 
(n = 49) 
Centres using 
other guidelines 
or no guidelines 
at all (n = 16) 
p-value 
Using propofol as first tier 
therapy 
    
- General policy 54 (83%) 42 (86%) 12 (75%) .42 
- Not general policy 11 (17%) 7 (14%) 4 (25%)  
Using barbiturates as first 
tier therapy 
    
- General policy 12 (19%) 7 (15%) 5 (31%) .15 
- Not general policy 52 (81%) 41 (85%) 11 (69%)  
Hypothermia use     
- General policy 16 (25%) 12 (25%) 4 (25%) 1.0 
- Not general policy 49 (75%) 37 (75%) 12 (75%)  
Hyperventilation use as first 
tier therapy 
    
- General policy 10 (15%) 5 (10%) 5 (31%) .10 
- Not general policy 55 (85%) 44 (90%) 11 (69%)  
Use of barbiturates in 
refractory ICP 
    
- General policy 21 (32%) 15 (31%) 6 (37%) .75 
- Not general policy 44 (68%) 34 (69%) 10 (63%)  
Use of transcranial Doppler     
- General policy 24 (38%) 18 (38%) 6 (38%) 1.0 
- Not general policy 40 (62%) 30 (62%) 10 (62%)  
Use of a jugular venous 
monitor 
    
- General policy 6 (9%) 6 (12%) 0 (0%) .32 
- Not general policy 58 (91%) 42 (88%) 16 (100%)  
Antiseizure prophylaxis 
with phenytoin 
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- General policy 20 (31%) 17 (35%) 3 (19%) .35 
- Not general policy 45 (69%) 32 (65%) 13 (81%)  
Antiseizure prophylaxis 
with levetiracetam 
    
- General policy 32 (49%) 28 (57%) 4 (25%) .04 
- Not general policy 33 (51%) 21 (43%) 12 (75%)  
Antiseizure prophylaxis 
with valproate 
    
- General policy 11 (17%) 8 (16%) 3 (19%) 1.0 
- Not general policy 54 (83%) 41 (84%) 13 (81%)  
Deep venous thrombosis 
prophylaxis use 
    
- General policy 62 (94%) 46 (94%) 16 (94%) 1.0 
- Not general policy 4 (6%) 3 (6%) 1 (6%)  
ICP monitoring in GCS<9 
and CT abnormalities 
    
- General policy 58 (91%) 44 (90%) 14 (93%) 1.0 
- Not general policy 6 (9%) 5 (10%) 1 (7%)  
ICP monitoring in GCS< 9 
and no CT abnormalities 
    
- General policy 15 (23%) 12 (25%) 3 (20%) 1.0 
- Not general policy 49 (77%) 37 (75%) 12 (80%)  
ICP monitoring in GCS 9-
12 and CT abnormalities 
    
- General policy 11 (17%) 8 (16%) 3 (20%) .71 
- Not general policy 53 (83%) 41 (84%) 12 (80%)  
Mannitol use     
- General policy 43 (66%) 34 (69%) 9 (56%) .37 
- Not general policy 22 (34%) 15 (31%) 7 (44%)  
Hypertonic saline use     
 11 
 
- General policy 44 (68%) 35 (71%) 9 (56%) .35 
- Not general policy 21 (32%) 14 (29%) 7 (44%)  
Conjunction of mannitol 
and hypertonic saline 
    
- General policy 14 (21%) 12 (25%) 2 (12%) .48 
- Not general policy 51 (79%) 37 (75%) 14 (88%)  
Administration of mannitol     
- Continuous 
infusion 
3 (5%) 1 (2%) 2 (14%) .14 
- Boluses 54 (95%) 42 (98%) 12 (86%)  
 278 
Table 1 – Comparisons in policy between centers that use Brain Trauma Foundation 279 
(BTF) Guidelines and those that use other guidelines or none at all 280 
 281 
